Skip to Content

Potiga Approval History

FDA Approved: Yes (Discontinued) (First approved June 10, 2011)
Brand name: Potiga
Generic name: ezogabine
Dosage form: Tablets
Company: GlaxoSmithKline
Treatment for: Seizures

Marketing Status: Discontinued

Potiga (ezogabine) is a potassium channel opener indicated for the adjunctive treatment of adults with partial-onset seizures.

Development History and FDA Approval Process for Potiga

DateArticle
Jun 13, 2011Approval Valeant and GlaxoSmithKline Announce U.S. FDA Approval of Potiga (ezogabine)
Apr 18, 2011Regulatory Update - GSK and Valeant Respond to FDA on Ezogabine
Dec  2, 2010GSK and Valeant Announce Receipt of U.S. FDA Complete Response Letter for ezogabine
Aug 12, 2010Ezogabine, an Investigational Anti-Epileptic Drug, Receives Positive Vote from FDA Advisory Committee
Dec 30, 2009FDA Accepts NDA Filing for Retigabine

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide